Breast Diseases Clinical Trial
Official title:
Evaluation of Longer Duration Use of the SAVI SCOUT Surgical Guidance System for Excision of Breast and Axillary Lesions in Neo-adjuvant Therapy Patients: A Pilot Study
Verified date | April 2020 |
Source | Envision Healthcare Scientific Intelligence, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the performance of FDA-cleared SAVI SCOUT Breast Localization and Surgical Guidance System (SCOUT) over a longer duration prior to surgery. The device is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue. The SCOUT device standard of care use is placement up to 30 days prior to surgery to assist surgeons in the localization and retrieval of breast/axillary lesions. Routine image-guided methods (Mammography, Ultrasound, and CT) are used. In this study, investigators will assess the longer term placement of the SCOUT device over an extended time (31 - 365 days) in order to address the needs of patients who require neoadjuvant treatment prior to definitive surgery.
Status | Completed |
Enrollment | 34 |
Est. completion date | April 4, 2019 |
Est. primary completion date | September 10, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Patient is willing and able to provide informed consent. Patient SCOUT device(s) is placed as part of routine care or study but before neoadjuvant treatment begins. - Patient is female. - Patient is between the ages of 18 and 90 years. - Patient has breast cancer and will undergo neoadjuvant therapy and excision at Memorial Healthcare System. - Patient is willing and able to comply with all study procedures and be available to follow-up for the duration of the study (1 - 13 months). - Patient reads or understands English or Spanish. Exclusion Criteria: - Patient is pregnant. - Patient has pacemaker or implantable defibrillators (These have not been bench tested as of September 2016). - Patient has known or suspected nickel allergy. - Patient is scheduled or receiving investigational drugs for neoadjuvant regimen. (This could confound UADE of this device.) - Patient has any condition that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study. - Patient has other malignancy except for adequately treated and cured basal or squamous cancer, curatively treated in situ disease or any other cancer for which the patient has been disease free for greater than or equal to 5 years. |
Country | Name | City | State |
---|---|---|---|
United States | Envision Physician Scientific Research, Inc. formerly Sheridan Healthcare, Inc. | Plantation | Florida |
Lead Sponsor | Collaborator |
---|---|
Envision Healthcare Scientific Intelligence, Inc. | Cianna Medical, Inc. |
United States,
Caudle AS, Yang WT, Mittendorf EA, Black DM, Hwang R, Hobbs B, Hunt KK, Krishnamurthy S, Kuerer HM. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015 Feb;150(2):137-43. doi: 10.1001/jamasurg.2014.1086. — View Citation
Cox CE, Garcia-Henriquez N, Glancy MJ, Whitworth P, Cox JM, Themar-Geck M, Prati R, Jung M, Russell S, Appleton K, King J, Shivers SC. Pilot Study of a New Nonradioactive Surgical Guidance Technology for Locating Nonpalpable Breast Lesions. Ann Surg Oncol. 2016 Jun;23(6):1824-30. doi: 10.1245/s10434-015-5079-x. Epub 2016 Feb 3. — View Citation
Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD; ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology. 2016 Apr;279(1):44-55. doi: 10.1148/radiol.2015150013. Epub 2015 Dec 1. — View Citation
Mango V, Ha R, Gomberawalla A, Wynn R, Feldman S. Evaluation of the SAVI SCOUT Surgical Guidance System for Localization and Excision of Nonpalpable Breast Lesions: A Feasibility Study. AJR Am J Roentgenol. 2016 Oct;207(4):W69-W72. Epub 2016 Jun 15. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Considered to Have a Successful Surgery | The primary endpoint of this study is successful surgery. Successful surgery (defined as one where the device stays in place and can be removed successfully during surgery) when this device is placed 31 - 365 days prior to surgery. Unsuccessful surgery is defined as one where the device does not stay in place and/or cannot be removed successfully during surgery) when this device is placed 31 - 365 days prior to surgery. | 31 - 365 days prior to surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04854304 -
Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts
|
||
Recruiting |
NCT01678170 -
Clinical Application of Breast Blood-oxygen Functional Imaging Technology
|
N/A | |
Completed |
NCT00039780 -
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
|
Phase 3 | |
Completed |
NCT02909452 -
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04535466 -
Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics
|
||
Recruiting |
NCT01917279 -
Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
|
Phase 3 | |
Recruiting |
NCT01427400 -
The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction
|
Phase 4 | |
Completed |
NCT05665894 -
Vacuum-Assisted Evacuation (VAE) Of Symptomatic and/or Voluminous Breast Haematomas Following Surgeries And Percutaneous Procedures: a Retrospective Analysis
|
||
Not yet recruiting |
NCT04088110 -
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
|
Phase 2 | |
Terminated |
NCT02997540 -
Effect of Body Position and Probe Position on the Localization of Breast Mass
|
||
Terminated |
NCT01140776 -
Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy
|
N/A | |
Recruiting |
NCT04911101 -
Performance Indicators and Patient Experience in 7G and 10G Vacuum-assisted Excision of Probably Benign Breast Lesions
|
N/A | |
Completed |
NCT04554316 -
Aesthetic Effect of Steri-Strip Orientation on Healing and Scar Appearance in Breast Surgery
|
N/A | |
Suspended |
NCT04151368 -
Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy
|
N/A | |
Completed |
NCT03743259 -
To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions
|
Phase 2 | |
Recruiting |
NCT04605575 -
Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05814224 -
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
|
N/A | |
Completed |
NCT02452333 -
Oncoplastic Approach to Excisional Breast Biopsies
|
N/A | |
Terminated |
NCT01372215 -
Multi-Compression Spot Mammography
|
N/A | |
Completed |
NCT00299039 -
T3AI-Pain After Breast Surgery
|
Phase 3 |